July 12, 2022
Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. as First Independent Board Member
Read More
March 22, 2022
SPOTLIGHT THERAPEUTICS RAISES $36.5 MILLION SERIES B TO ADVANCE A PIPELINE OF CELL-TARGETED IN VIVO CRISPR GENE EDITING BIOLOGICS
Read More
November 20, 2020
Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics
Read More
